Abstract
Recent years have seen rising incidence of dengue and large outbreaks of Zika and chikungunya, which are all caused by viruses transmitted by Aedes aegypti mosquitoes. In most settings, the primary intervention against Aedes-transmitted viruses is vector control, such as indoor, ultra-low volume (ULV) spraying. Targeted indoor residual spraying (TIRS) has the potential to more effectively impact Aedes-borne diseases, but its implementation requires careful planning and evaluation. The optimal time to deploy these interventions and their relative epidemiological effects are not well understood, however. We used an agent-based model of dengue virus transmission calibrated to data from Iquitos, Peru to assess the epidemiological effects of these interventions under differing strategies for deploying them. Specifically, we compared strategies where spray application was initiated when incidence rose above a threshold based on incidence in recent years to strategies where spraying occurred at the same time(s) each year. In the absence of spraying, the model predicted 361,000 infections [inter-quartile range (IQR): 347,000 – 383,000] in the period 2000-2010. The ULV strategy with the fewest median infections was spraying twice yearly, in March and October, which led to a median of 172,000 infections [IQR: 158,000 – 183,000] over the 11-year study period, a 52% reduction from baseline. Compared to spraying once yearly in September, the best threshold-based strategy utilizing ULV had fewer median infections (254,000 vs. 261,000), but required more spraying (351 vs. 274 days). For TIRS, the best strategy was threshold-based, which led to the fewest infections of all strategies tested (9,900; [IQR: 8,720 – 11,400], a 94% reduction), and required fewer days spraying than the equivalent ULV strategy (280). Although spraying twice each year is likely to avert the most infections, our results indicate that a threshold-based strategy can become an alternative to better balance the translation of spraying effort into impact, particularly if used with a residual insecticide.
Author Summary Over half of the world’s population is at risk of infection by dengue virus (DENV) from Aedes aegypti mosquitoes. While most infected people experience mild or asymptomatic infections, dengue can cause severe symptoms, such as hemorrhage, shock, and death. A vaccine against dengue exists, but it can increase the risk of severe disease in people who have not been previously infected by one of the four DENV serotypes. In many places, therefore, the best currently available way to prevent outbreaks is by controlling the mosquito population. Our study used a simulation model to explore alternative strategies for deploying insecticide in the city of Iquitos in the Peruvian Amazon. Our simulations closely matched empirical patterns from studies of dengue’s ecology and epidemiology in Iquitos, such as mosquito population dynamics, human household structure, demography, human and mosquito movement, and virus transmission. Our results indicate that an insecticide that has a long-lasting, residual effect will have the biggest impact on reducing DENV transmission. For non-residual insecticides, we find that it is best to begin spraying close to the start of the dengue transmission season, as mosquito populations can rebound quickly and resume previous levels of transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SMC, GFCE, GMVP, ACM, TWS, RCR, and TAP were supported by grant P01AI098670 (TWS, PI) from the National Institutes of Health, National Institute for Allergy and Infectious Disease (https://www.niaid.nih.gov). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
Funding SMC, GFCE, GMVP, ACM, TWS, RCR, and TAP were supported by grant P01AI098670 (TWS, PI) from the National Institutes of Health, National Institute for Allergy and Infectious Disease (https://www.niaid.nih.gov). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests The authors have declared that no competing interests exist.
Data Availability
All relevant data and code will soon be made available on GitHub, with synthetic data used for house locations.
